ORIGINAL RESEARCH
Published on 09 May 2025
The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade
doi 10.3389/fimmu.2025.1486799
- 504 views